Press "esc" to clear
Go to Advanced Search

Showing results

110 of 118

Article ID: 697277

Ludwig Cancer Research and Cancer Research Institute Launch Clinical Trial Combining Virotherapy and Immunotherapy to Treat Advanced Colorectal and Ovarian Cancers

Ludwig Cancer Research

Ludwig Cancer Research and the Cancer Research Institute (CRI) announce the initiation of a clinical trial to evaluate the combination of ONCOS-102, an experimental anti-tumor virotherapy, with the checkpoint blockade antibody IMFINZI® (durvalumab) for advanced ovarian and colorectal cancers.

Released:
11-Jul-2018 12:00 PM EDT
EXPERT AVAILABLE
Open in New Tab
Comment

Article ID: 697154

Ludwig-Developed Candidate Cancer Drug May Be Effective Against Broader Class of Brain Cancers

Ludwig Cancer Research

A Ludwig Cancer Research study explains why a particular mutation in the epidermal growth factor receptor (EGFR), a cell surface protein, results in more aggressive tumors and poorer overall survival of patients diagnosed with the brain cancer glioblastoma multiforme (GBM).

Released:
9-Jul-2018 4:15 PM EDT
EXPERT AVAILABLE
Open in New Tab
Comment
  • Embargo expired:
    31-May-2018 11:00 AM EDT

Article ID: 695136

How Might Baking Soda Boost Cancer Therapy?

Ludwig Cancer Research

A Ludwig Cancer Research study has uncovered an entirely novel mechanism by which cells enter a state of dormancy as tissues starved of oxygen become increasingly acidic. The study, led by Chi Van Dang, scientific director of the Ludwig Institute for Cancer Research, has potentially significant implications for cancer therapy: Large swaths of solid tumors are often deprived of oxygen, and cells in such patches are thought to be a major source of drug resistance and disease relapses.

Released:
25-May-2018 12:00 PM EDT
EXPERT AVAILABLE
Open in New Tab
Comment

Article ID: 695260

ASCO to Honor Ludwig Scientists at 2018 Annual Meeting

Ludwig Cancer Research

The American Society of Clinical Oncology (ASCO) will honor two Ludwig scientists at its 2018 Annual Meeting in Chicago, Ill., June 1-5, 2018.

Released:
30-May-2018 9:00 AM EDT
EXPERT AVAILABLE
Open in New Tab
Comment

Article ID: 692594

Ludwig Scientists Share New Findings on Personalized Cancer Treatments, Immunotherapy and the Tumor Microenvironment at 2018 AACR Annual Meeting

Ludwig Cancer Research

Ludwig Cancer Research released today the full scope of findings to be presented by Ludwig researchers at this year’s American Association for Cancer Research (AACR) Annual Meeting in Chicago, Ill., April 14-18, 2018. Research conducted by more than 100 Ludwig scientists will be presented in symposiums, plenaries, town meetings, education sessions and poster sessions.

Released:
11-Apr-2018 4:00 PM EDT
EXPERT AVAILABLE
Open in New Tab
Comment
LanaAlexGeorge.png
  • Embargo expired:
    11-Apr-2018 2:00 PM EDT

Article ID: 692575

Ludwig Researchers Devise and Test Pioneering Personalized Cancer Vaccine for Ovarian Cancer

Ludwig Cancer Research

A Ludwig Cancer Research study has shown that an entirely new type of personalized cancer vaccine induces novel, potent and clinically effective immune responses in patients receiving a combination of standard therapies for recurrent, stage III and IV ovarian cancer.

Released:
10-Apr-2018 6:00 PM EDT
EXPERT AVAILABLE
Open in New Tab
Comment
HarariCoukos.png

Article ID: 691032

Ludwig Study Extends the Potential for Personalized Immunotherapy to a Large Variety of Cancers

Ludwig Cancer Research

A Ludwig Cancer Research study shows that ovarian cancer, which has proved resistant to currently available immunotherapies, could be susceptible to personalized immunotherapy. Led by Ludwig Lausanne investigator Alexandre Harari and George Coukos, director of the Ludwig Institute for Cancer Research, Lausanne, the study shows that ovarian tumors harbor highly reactive killer T cells—which kill infected and cancerous cells—and demonstrates how they can be identified and selectively grown for use in personalized, cell-based immunotherapies.

Released:
15-Mar-2018 6:00 AM EDT
EXPERT AVAILABLE
Open in New Tab
Comment
TokerImagetoUse.jpg

Article ID: 687056

Ludwig Researchers Uncover Mechanism Behind a Metabolic Vulnerability of Certain Breast Cancers

Ludwig Cancer Research

Many cancer cells are relatively sensitive to the deprivation of an essential amino acid known as methionine. Now, a Ludwig Cancer Research study published in the journal Science Signaling and led by Alex Toker, an investigator in the Ludwig Center at Harvard, has elucidated one mechanism behind that dependency.

Released:
19-Dec-2017 2:00 PM EST
EXPERT AVAILABLE
Open in New Tab
Comment
DonCleveland.png

Article ID: 686082

Ludwig Cancer Research Scientist Don Cleveland Wins Breakthrough Award

Ludwig Cancer Research

Ludwig Cancer Research extends its warmest congratulations to Don Cleveland, who has been a Member of the Ludwig Institute for Cancer Research since 1995 and today was awarded the prestigious Breakthrough Prize.

Released:
3-Dec-2017 8:00 PM EST
EXPERT AVAILABLE
Open in New Tab
Comment
Ralph.jpg

Article ID: 685643

Ludwig Researchers Unravel Novel Mechanism by Which Tumors Grow Resistant to Radiotherapy

Ludwig Cancer Research

A Ludwig Cancer Research study has uncovered a key mechanism by which tumors develop resistance to radiation therapy and shown how such resistance might be overcome with drugs that are currently under development.

Released:
23-Nov-2017 9:00 AM EST
EXPERT AVAILABLE
Open in New Tab
Comment

Showing results

110 of 118





Chat now!